The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents

In Vivo

Volumn 22, Issue 3, 2008, Pages 385-390

  Asimakopoulou, Athanasia P ^a   Theocharis, Achilleas D ^a   Tzanakakis, George N ^b   Karamanos, Nikos K ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Cancer; Chondroitin sulfate; Modified chonroitin sulfate; Proteoglycans; Review

Indexed keywords

ANTINEOPLASTIC AGENT; CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; CHONDROITIN SULFATE; CHONDROITIN SULFATE D; CHONDROITIN SULFATE DERIVATIVE; CHONDROITIN SULFATE E; CHONDROITIN SULFATE H; CISPLATIN; DERMATAN SULFATE; DIPENTADECYCLOXYBENZAMIDINE; FUCOSYLATED CHONDROITIN SULFATE; HEPARIN LYASE; L SELECTIN; LIPOSOME; N ACETYLGALACTOSAMINE 4 SULFATASE; PADGEM PROTEIN; TRX 20;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CONFORMATIONAL TRANSITION; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; MESOTHELIOMA; METASTASIS INHIBITION; NONHUMAN; PANCREAS CANCER; PROSTAGLANDIN SYNTHESIS; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; SULFATION;

EID: 45949083498     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Prabhakar V and Sasisekharan R: The biosynthesis and catabolism of galactosaminoglycans. Adv Pharmacol 53: 69-115, 2006.
2. Karamanos NK, Syrokou A, Vanky P, Nurminen M and Hjerpe A: Determination of 24 variously sulfated galactosaminoglycan- and hyaluronan-derived disaccharides by high-performance liquid chromatography. Anal Biochem 221: 189-199, 1994.
3. Lamari FN and Karamanos NK: Structure of chondroitin sulfate. Adv Pharmacol 53: 33-34, 2006.
4. Theocharis AD, Tsolakis I, Tzanakakis GN and Karamanos NK: Chondroitin sulfate as a key molecule in the development of atherosclerosis and cancer progression. Adv Pharmacol 53: 281-295, 2006.
5. Wegrowski Y and Maquart F: Chondroitin sulfate in tumor progression. Adv Pharmacol 53: 297-321, 2006.
6. Labropoulou VT, Theocharis AD, Ravazoula P, Peromenis P, Hjerpe A, Karamanos NK and Kalofonos HP: Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumors. Histopathol 49: 582-593, 2006.
7. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Tilley WD, Skinner JM and Horsfall DJ: Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin Cancer Res 3: 983-992, 1997.
8. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR and Horsfall DJ: Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 4: 963-971, 1998.
9. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG and Horsfall DJ: Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 8: 1054-1060, 2002.
10. Ricciardelli C, Russell DL, Ween, MP, Mayne K, Suwiwat S, Byers S, Marshall VR, Tilley WD and Horsfall DJ: Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem 282: 10814-10825, 2007.
11. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, Raymond WA, Tilley WD and Horsfall DJ: Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 10: 2491-2498, 2004.
12. Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD, Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD, Skinner JM and Horsfall DJ: Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Clin Cancer Res 15: 2324-2328, 1999.
13. Tzanakakis GN, Karamanos NK, Klominek J and Hjerpe A: Glycosaminoglycans from two human malignant mesothelioma cells lines: determination, distribution, and effect of platelet-derived growth factor on their synthesis. Biochem Cell Biol 73: 59-66, 1995.
14. Tzanakakis GN, Karamanos NK, Syrokou A and Hjerpe A: Effect of insulin and epidermal growth factors on the synthesis of glycosaminoglycans/ proteoglyeans in cultured human malignant mesothelioma cells of different phenotypic morphology. APMIS 104: 718-728, 1996.
15. Syrokou A, Tzanakakis G, Tsegenidis T, Hjerpe A and Karamanos NK: Effects of glycosaminoglycans on proliferation of epithelial and fibroblast human malignant mesothelioma cells: a structure-function relationship. Cell Prolif 81: 85-99, 1999.
16. Theocharis AD: Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin. Biochimic Biophys Acta 1588: 165-172, 2002.
17. Skandalis SS, Kletsas D, Kyriakopoulou D, Stavropoulos M and Theocharis DA: The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications of versican and decorin. Biochim Biophys Acta 1760: 1217-1225, 2006.
18. Toyama-Sorimachi N, Sorimachi H, Tobita Y, Kitamura F, Yagita H, Suzuki K and Miyasaka M: A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. J Biol Chem 270: 7437-7444, 1995.
19. Kawashima. H, Hirose M, Hirose J, Nagakubo D, Plaas AH and Miyasaka M: Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J Biol Chem 275: 35448-35456, 2000.
20. Fujimoto T, Kawashima H, Tanaka T, Hirose M, Toyama-Sorimachi N, Matsuzawa Y and Miyasaka M: CD44 binds a chondroitin sulfate proteoglycan, aggrecan. Int Immunol 13: 359-366, 2001.
21. Toyama-Sorimachi N, Kitamura F, Habuchi H, Tobita Y, Kimata K and Miyasaka M: Widespread expression of chondroitin sulfate-type serglycins with CD44 binding ability in hematopoietic cells. J Biol Chem 272: 26714-26719, 1997.
22. Faassen AE, Schrager JA, Klein DJ, Oegema TR, Couchman JR and McCarthy JB: A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J Cell Biol 116: 521-531, 1992.
23. Henke CA, Roongta U, Mickelson DJ, Knutson JR and McCarthy JB: CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix. J Clin Invest 9: 2541-2552, 1996.
24. Theocharis AD, Seidel C, Borset M, Dobra K, Baykov V, Labropoulou V, Kanakis I, Dalas E, Karamanos NK, Sundan A and Hjerpe A: Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J Biol Chem 281: 35116-35128, 2006.
25. Luo J, Kato M, Wang H, Bernfield M and Bischoff J: Heparan sulfate and chondroitin sulfate proteoglycans inhibit E-selectin binding to endothelial cells. J Cell Bioohem. 80: 522-531, 2001.
26. Monzavi-Karbassi B, Stanley JS, Hennings L, Jousheghany F and Artaud C: Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breas~ cancer cell lines. Int J Cancer 120: 1179-1191, 2007.
27. Iida J, Wilhelmson KL, Janet NG, Lee P, Morrison C, Tam E, Overall CM and McCarthy JB: Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in activation of pro-MMP-2 (pro-gelatinase A). Biochem J 403: 553-563, 2007.
28. Karamanos NK, Syrokou A, Vanky P, Nunninen M and Hjerpe A: Determination of 24 variously sulfated galactosaminoglycan- and hyaluronan-derived disaccharides by high-performance liquid chromatography. Anal Biochem 221: 189-199, 1994.
29. Fthenou E, Zafiropoulos A, Katonis P, Tsatsakis A, Karamanos NK and Tzanakakis GN: Chondroitin sulfate prevents platelet derived growth factor-mediated phosphorylation of PDGF-Rbeta in normal human fibroblasts severely impairing mitogenic responses. J Cell Biochem, 2007, in press.
30. Nicitovic D, Zafiropoulos A, Tzanakakis GN, Karamanos NK and Tsatsakis AM: Effects of glycosaminoglycans on cell proliferation of normal osteoblasts and human osteosarcoma cells depend on their type and fine chemical compositions. Anticancer Res 25: 2851-2856, 2005.
31. Pumphrey CY, Theus AM, Li S, Parrish RS and Sanderson RD: Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res 1: 3722-3728, 2002.
32. Kawashima H, Atarashi K, Hirose M, Hirose J, Yamada S, Sugahara K and Miyasaka M: Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1-3GalNAc (4,6-O-disulfate) interact with L- and P-selectin and chemokines. J Biol Chem 277: 12921-12930, 2002.
33. Borsig L, Wang L, Cavalcante MCM, Cardilo-Reis L, Ferreira PL, Mourao PAS, Esko JD and Pavao MSG: Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. J Biol Chem 98: 14984-14991, 2007.
34. Liu Y, Yang H, Otaka K, Takatsuki H and Sakanishi A: Effects of vascular endothelial growth factor (VEGF) and chondroitin sulfate A on human monocyte THP-1 cell migration. Colloids Surf B Biointerfaces 43: 216-220, 2005.
35. Maeda M, Takasuka N, Suga T, Uehara N and Hoshi A: Antitumor activity of a new series of platinum complexes: trans(+/-)-1,2- cyclohexanediammineplatinum(II) conjugated to acid polysaccharides. Anticancer Drugs 4: 167-171, 1993.
36. Weikkolainen K, Aitio O, Blomqvist M, Natimen J and Helin J: Conjugation of oligosaccharides by reductive amination to amine modified chondroitin oligomer and gamma-cyclodextrin. Glycoconj J 24: 157-165, 2007.
37. Hwang T, Lee W, Hua S and Fang J: Cisplatin encapsulated in phospatidylethanolamine liposomes enhances the in vitro intratumor drug accumulation against melanomas. J Dermatol. Sc 46: 11-20, 2007.
38. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H and Miyasaka M: Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 62: 4282-4288, 2002.
39. Patel M, Shah T and Amin A: Therapeutic opportunities in colon-specific drug delivery systems. Crit Rev Ther Drug Carrier Syst 24: 147-202, 2007.